Oppenheimer & Co’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.16M Buy
+39,422
New +$3.25M 0.04% 455
2025
Q4
Sell
-81,782
Closed -$6.36M 1633
2025
Q3
$6.36M Buy
81,782
+7,141
+10% +$558K 0.08% 281
2025
Q2
$5.84M Buy
74,641
+8,747
+13% +$652K 0.08% 279
2025
Q1
$4.78M Buy
65,894
+5,853
+10% +$419K 0.07% 302
2024
Q4
$4.44M Buy
60,041
+21,855
+57% +$1.53M 0.07% 318
2024
Q3
$2.52M Buy
38,186
+1,441
+4% +$105K 0.04% 478
2024
Q2
$3.39M Buy
36,745
+10,492
+40% +$929K 0.05% 368
2024
Q1
$2.51M Buy
26,253
+4,977
+23% +$418K 0.04% 447
2023
Q4
$1.62M Sell
21,276
-10,813
-34% -$752K 0.03% 559
2023
Q3
$2.22M Sell
32,089
-6,463
-17% -$519K 0.05% 427
2023
Q2
$3.64M Sell
38,552
-1,050
-3% -$91.3K 0.07% 299
2023
Q1
$3.28M Sell
39,602
-18,758
-32% -$1.47M 0.07% 314
2022
Q4
$4.35M Buy
58,360
+14,635
+33% +$1.13M 0.1% 249
2022
Q3
$3.61M Sell
43,725
-1,608
-4% -$155K 0.08% 287
2022
Q2
$4.31M Buy
45,333
+2,202
+5% +$228K 0.09% 261
2022
Q1
$5.08M Sell
43,131
-1,118
-3% -$125K 0.09% 274
2021
Q4
$5.73M Buy
44,249
+1,826
+4% +$213K 0.1% 233
2021
Q3
$4.8M Buy
42,423
+1,970
+5% +$225K 0.09% 262
2021
Q2
$4.19M Sell
40,453
-4,257
-10% -$401K 0.08% 308
2021
Q1
$3.74M Sell
44,710
-13,309
-23% -$1.13M 0.07% 309
2020
Q4
$5.29M Sell
58,019
-3,624
-6% -$301K 0.11% 209
2020
Q3
$4.92M Buy
61,643
+12,632
+26% +$986K 0.12% 185
2020
Q2
$3.39M Sell
49,011
-11,049
-18% -$785K 0.09% 255
2020
Q1
$3.78M Buy
60,060
+22,770
+61% +$1.64M 0.11% 192
2019
Q4
$2.9M Buy
37,290
+7,059
+23% +$551K 0.07% 307
2019
Q3
$2.22M Sell
30,231
-5,451
-15% -$383K 0.06% 375
2019
Q2
$2.2M Sell
35,682
-16,698
-32% -$1.01M 0.06% 368
2019
Q1
$3.34M Sell
52,380
-2,547
-5% -$145K 0.09% 259
2018
Q4
$2.8M Buy
54,927
+4,284
+8% +$217K 0.09% 261
2018
Q3
$2.94M Buy
50,643
+9,972
+25% +$488K 0.07% 294
2018
Q2
$1.97M Sell
40,671
-18,114
-31% -$845K 0.05% 395
2018
Q1
$2.73M Sell
58,785
-1,338
-2% -$58.1K 0.07% 318
2017
Q4
$2.26M Buy
60,123
+30,573
+103% +$1.12M 0.06% 354
2017
Q3
$1.08M Sell
29,550
-21,138
-42% -$806K 0.03% 589
2017
Q2
$2M Sell
50,688
-2,703
-5% -$98.7K 0.06% 390
2017
Q1
$1.67M Sell
53,391
-7,791
-13% -$244K 0.05% 436
2016
Q4
$1.91M Sell
61,182
-124,134
-67% -$4.02M 0.06% 388
2016
Q3
$7.45M Sell
185,316
-22,740
-11% -$856K 0.22% 102
2016
Q2
$6.92M Buy
208,056
+5,898
+3% +$202K 0.21% 105
2016
Q1
$5.94M Buy
202,158
+131,541
+186% +$3.63M 0.18% 124
2015
Q4
$1.86M Buy
70,617
+19,317
+38% +$502K 0.06% 373
2015
Q3
$1.22M Buy
51,300
+6,048
+13% +$146K 0.04% 509
2015
Q2
$1.07M Sell
45,252
-108
-0.2% -$2.44K 0.03% 606
2015
Q1
$1.08M Buy
45,360
+504
+1% +$11.3K 0.03% 607
2014
Q4
$953K Buy
44,856
+13,722
+44% +$276K 0.03% 620
2014
Q3
$530K Sell
31,134
-288
-0.9% -$4.55K 0.02% 828
2014
Q2
$450K Sell
31,422
-13,248
-30% -$180K 0.01% 890
2014
Q1
$552K Sell
44,670
-32,946
-42% -$380K 0.02% 789
2013
Q4
$850K Buy
77,616
+3,264
+4% +$36.8K 0.03% 618
2013
Q3
$863K Buy
+74,352
New +$870K 0.03% 592

Other funds holding EW

Oppenheimer & Co's EW Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in Edwards Lifesciences (EW) in Q1 2026: 39,422 shares worth $3.16M. The stake represents 0.04% of the portfolio and ranks #455 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in EW as recently as Q3 2025.

Oppenheimer & Co first reported a position in EW in Q3 2013 and has held it in 50 quarters since. The position peaked at $7.45M in Q3 2016. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Oppenheimer & Co held 39,422 shares of Edwards Lifesciences worth $3.16M as of Q1 2026.
  • Edwards Lifesciences was a new Oppenheimer & Co position in Q1 2026.
  • Edwards Lifesciences made up 0.04% of Oppenheimer & Co's portfolio in Q1 2026, its #455 holding.
  • Oppenheimer & Co first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 50 quarters since.
  • Oppenheimer & Co's Edwards Lifesciences position peaked at $7.45M in Q3 2016.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.